Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patients
Open Access
- 15 July 2004
- journal article
- fast track
- Published by Wiley in International Journal of Cancer
- Vol. 112 (5) , 733-737
- https://doi.org/10.1002/ijc.20487
Abstract
Thymidylate synthase (TS) is the primary target of 5‐fluorouracil (5‐FU). A VNTR polymorphism in the TS promoter region is associated with the efficacy of 5‐FU‐based chemotherapy in colorectal cancer. A common G>C SNP at the 12th nucleotide of the second repeat in the TS*3 alleles has been recently described. The combination of SNP and VNTR allows the definition of 3 TS alleles: *2, *3G and *3C. The aim of our study was to evaluate the predictive value of clinical response and survival of these new defined TS alleles. TS genotypes of 89 patients diagnosed with metastatic colorectal cancer and undergoing 5‐FU‐based chemotherapy were carried out. The clinical outcome was evaluated according to the genotype (high expression genotype: *2R/*3G; *3C/*3G; *3G/*3G; and low expression genotype: *2R/*2R; *2R/*3C; *3C/*3C. A higher overall response was observed in the group of patients with a low expression genotype (p = 0.035). The probability of achieving a clinical response of patients with a low expression‐related genotype was 2.9 higher than that of the other group (95% CI = 1.03–5.6, p = 0.04). The median time to progression was 12 months and 9 months in the low and high expression groups, respectively (p = 0.07, log rank test). Overall survival was significantly longer in the low expression group. In this group the median OS was not achieved at 50 months of follow‐up in contrast to the 20 months observed in the high expression group (p = 0.03). TS genotype was an independent predictor of progression‐free and overall survival in the Cox regression models after adjustment to the other clinical variables. The selection of patients who are likely to respond to 5‐FU therapy may be considerably improved if the TS genotype were to include both the VNTR and the SNP located within the promoter region of the gene.Keywords
Funding Information
- Spanish Ministry of Science and Technology (SAF2001-1055)
This publication has 19 references indexed in Scilit:
- Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for a 28-bp Polymorphism in theTSGeneClinical Cancer Research, 2004
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003
- Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic AnalysesJournal of Clinical Oncology, 2002
- Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2002
- Length Polymorphism of Thymidylate Synthase Regulatory Region in Chinese Populations and Evolution of the Novel AllelesBiochemical Genetics, 2002
- Ethnic Variation in the Thymidylate Synthase Enhancer Region Polymorphism among Caucasian and Asian PopulationsGenomics, 1999
- Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase.Cell Structure and Function, 1995
- A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Research, 1988
- Nucleotide sequence of a functional cDNA for human thymidylate synthaseNucleic Acids Research, 1985
- Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparationsCancer, 1981